GEORGETOWN, Texas–(BUSINESS WIRE)–October 18, 2022–
AustinPx, Pharmaceuticals and Manufacturing, a contract development and manufacturing organization (CDMO), today announced the appointment of Derek Hennecke and Marshall Crew as independent members of its Board of Directors. Appointments provide additional experienced CDMO leadership to drive growth in complex formulation and manufacturing market
“I am delighted to welcome Derek and Marshall to the AustinPx Board of Directors, two seasoned CDMO leaders with extensive expertise,” said Tim Scott, President and CEO and Board Member. from AustinPx. “Derek’s experience building successful global businesses, including founding and leading early-stage oral drug development, manufacturing and clinical supply companies, is the perfect expertise to help us lead growth. AustinPx’s business and market strategies. company, is the exact perspective we need to take KinetiSol ® technology to the next level and represents a stamp of approval on the potential of our amorphous dispersion technology.
Mr. Hennecke currently sits on several boards of directors, he is Chairman of the Board of Directors of Microsize and Particle Dynamics and Director of the Board of Directors of Grand River Aseptic Manufacturing, Inceptor Bio, Kineticos Disruptor Fund and Friedreich’s Ataxia Research Alliance. Previously, he was founder and CEO of Xcelience (acquired by Capsugel, now Lonza), director of the board of directors of Oragenics, vice president and general manager of MDS Pharma Services, and held various management positions. at DSM Biologics, DSM Anti-Infectives and Gist-Brocades in the Netherlands, Mexico and Egypt.
Dr. Crew was co-founder and CEO of Agere, a CDMO specializing in spray-dried dispersions and oral bioavailability of poorly soluble molecules which was acquired by Patheon in 2015. Following the acquisition of Agere, he remained at Patheon as Vice President of Scientific Excellence for Pharmaceutical Development Services, then Senior Vice President of Innovation. Following the acquisition of Patheon by Thermo Fisher Scientific, Marshall was appointed Group Vice President and Chief Strategy Officer, leading the Pharma Services Group’s growth activities. Dr. Crew currently sits on the boards of BioIVT, Formulated Solutions and Selkirk Pharma.
“We are delighted to welcome Derek and Marshall to the AustinPx Board of Directors, bringing proven CDMO expertise that will be invaluable as directors,” said Shaun Kirkpatrick, president of Research Corporation Technologies Partners and chairman of the AustinPx Board of Directors. “The addition of Derek and Marshall, alongside Tim – three commercially successful CDMO founding executives who helped pioneer the widespread use of amorphous spray drying and other technologies – further demonstrates our commitment to growing our business. ‘AustinPx and realizing the full market potential of KinetiSol technology, our next-generation amorphous dispersion platform.’
AustinPx, Pharmaceuticals and Manufacturing is a contract development and manufacturing organization (CDMO) providing analytical development and cGMP formulation and manufacturing services for small molecule drugs. We specialize in phase-appropriate development strategies, speed-to-clinic and time-to-market strategies, and improving the bioavailability of poorly soluble molecules – including our next-generation amorphous dispersion platform, KinetiSol®. For more information, www.AustinPx.com.
Show source version on businesswire.com:https://www.businesswire.com/news/home/20221018005982/en/
CONTACT: Elizabeth Hickman
KEYWORD: TEXAS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH CLINICAL TRIALS
Copyright BusinessWire 2022.
PUBLISHED: 10/18/2022 11:28 AM / DISK: 10/18/2022 11:28 AM
Copyright BusinessWire 2022.